Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese firms JCR Pharmaceuticals and Sumitomo Dainippon Pharma have executed an agreement to study the feasibility of applying JCR’s blood-brain barrier (BBB) penetration technology, J-Brain Cargo, to discover new treatment in the psychiatry and neurology area.
Subscribe to our email newsletter
As part of the deal, the two firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo’s choice, with a view to develop new pharmaceutical products for these disorders.
JCR’s J-Brain Cargo technology enables delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells.
A study conducted by JCR confirmed BBB penetration of J-Brain Cargo combined target substance as 20 to 100 times the target substance alone.
J-Brain Cargo provides pharmaceutical compounds of low to high molecules with the capacity to pass through the BBB.
In a statement, the company noted that a substantially large portion of the pharmaceutical injected intravenously should be able to reach inside the brain and show its efficacy.
JCR is engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases.